Publications

Authors: Marc Evans, Susanne Engberg, Mads Faurby, João Diogo Da Rocha Fernandes, Pollyanna Hudson, William Polonsky Abstract We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world noninterventional studies (published between 2010 and October 2020) reporting estimates of

Authors: Stephanie Edwards, Xuanyao He, Wenjie Wang, Jiat-Ling Poon, Eric Meadows, David Price, Jennal Johnson, Howard Wolpert, William Polonsky Abstract Objective: This study used connected pen to determine missed bolus dose (MBD) frequency during masked and unmasked continuous glucose monitoring (CGM) periods and examined its link with time-in-range (TIR), time-above-range (TAR), time-below-range (TBR), and key participant characteristics in people with

Authors: Grazia Aleppo, Roy W. Beck, Ryan Bailey, Katrina J. Ruedy, Peter Calhoun, Anne L. Peters, Rodica Pop-Busui, Athena Philis-Tsimikas, Shichun Bao, Guillermo Umpierrez, Georgia Davis, Davida Kruger, Anuj Bhargava, Laura Young, John B. Buse, Janet B. McGill, Thomas Martens, Quang T. Nguyen, Ian Orozco, William Biggs, K. Jean Lucas, William H. Polonsky, David Price, Richard M. Bergenstal, MOBILE Study

Authors: Thomas Martens, Roy W Beck, Ryan Bailey, Katrina J Ruedy, Peter Calhoun, Anne L Peters, Rodica Pop-Busui, Athena Philis-Tsimikas, Shichun Bao, Guillermo Umpierrez, Georgia Davis, Davida Kruger, Anuj Bhargava, Laura Young, Janet B McGill, Grazia Aleppo, Quang T Nguyen, Ian Orozco, William Biggs, K Jean Lucas, William H Polonsky, John B Buse, David Price, Richard M Bergenstal, MOBILE Study

Authors: William Polonsky, Cory Gamble, Neeraj Iyer, Mona Martin, Carol Hamersky Abstract Objective: Despite the demonstrated benefits of glucagon-like peptide 1 (GLP-1) receptor agonist therapy, adherence and persistence with this therapy is often challenging. The purpose of this study was to expand current understanding of patients’ experiences, motivations, and challenges relevant to their persistence with GLP-1 receptor agonist therapy. Design

Authors: W H Polonsky, A L Fortmann, D Price, L Fisher Abstract Aims: To investigate the problem of adults with type 1 diabetes (T1D) who purposefully keep their glucose levels low, and to explore contributors to, and possible impact of, this potentially dangerous phenomenon. Methods: We developed three self-report items as a means to identify individuals who endorse a consistent

Authors: Howard Wolpert, William H Polonsky, David Rodbard Abstract The advent of connected insulin pens will generate an avalanche of digital insulin data, especially in the context of prandial- and multiple daily injection-insulin regimens. There is a need for the diabetes community to develop standards for such data, analogous to what has been achieved using the ambulatory glucose profile and

Authors: Frank J Snoek, Lawrence Fisher, William H Polonsky, Heather Stuckey, Danielle Hessler, Tricia Tang, Norbert Hermanns, Xavier Mundet, Maria Silva, Jackie Sturt, Kentaro Okazaki, Irene Hadjiyianni, Urvi Desai, Magaly Perez-Nieves Abstract Despite the demonstrated benefits of using insulin, nearly a third of the patients with type 2 diabetes (T2D) are initially reluctant to initiate insulin therapy when it is

Authors: Chioma Uzoigwe, Michael Radin, Carol M Hamersky, Mitch DeKoven, Cassie Holt, Swapna Karkare, William H Polonsky Abstract Purpose: Five quality of life (QoL) domains are particularly important to patients with type 2 diabetes (T2D) using basal insulin-sense of physical well-being, sense of safety regarding hypoglycemia, sense of diabetes as burdensome, feelings of freedom and flexibility, and sleep quality. Methods:

Authors: Arndís F Ólafsdóttir, Jan Bolinder, Tim Heise, William Polonsky, Magnus Ekelund, Magnus Wijkman, Aldina Pivodic, Elsa Ahlén, Erik Schwarcz, Thomas Nyström, Jarl Hellman, Irl B Hirsch, Marcus Lind Abstract Aim: To identify responders to continuous glucose monitoring (CGM) in relation to reductions in HbA1c and percentage of time spent in hypoglycaemia after initiation of CGM for individuals with type